Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643366 | 0.99 | TP53 (0.61) | TP53HRH3MEN1KMT2AHTR3A | |
| SCHEMBL1645755 | 0.87 | TP53 (0.54) | TP53HRH3MEN1KMT2AHTR3A | |
| SCHEMBL1644052 | 0.87 | HRH3 (0.54) | TP53HRH3MEN1KMT2AHTR3A | |
| SCHEMBL1644303 | 0.85 | HRH3 (0.53) | TP53HRH3MEN1KMT2AMCHR1 | |
| SCHEMBL13648922 | 0.85 | HRH3 (0.59) | TP53HRH3MEN1KMT2AHTR3A | |
| SCHEMBL1644372 | 0.85 | HRH3 (0.51) | TP53HRH3MEN1KMT2AHTR3A | |
| Hydrochloric Acid SCHEMBL3973032 | 0.84 | HRH3 (0.58) | TP53HRH3MEN1KMT2AHTR3A | |
| SCHEMBL20176398 | 0.83 | KDM4E (0.53) | TP53HRH3MEN1KMT2AMCHR1 | |
| SCHEMBL1644219 | 0.83 | HRH3 (0.52) | TP53HRH3MEN1KMT2AMCHR1 | |
| SCHEMBL10271626 | 0.81 | SIRT2 (0.53) | TP53HRH3KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | TP53 3973/4885HRH3 556/4885MEN1 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.